What are the current guideline-recommended ages and intervals for cervical cancer screening with Pap smears in average‑risk females, and how do recommendations differ for high‑risk populations? | Rounds What are the current guideline-recommended ages and intervals for cervical cancer screening with Pap smears in average‑risk females, and how do recommendations differ for high‑risk populations? | Rounds
Loading...

What are the current guideline-recommended ages and intervals for cervical cancer screening with Pap smears in average‑risk females, and how do recommendations differ for high‑risk populations?

Medical Advisory Board
All articles are reviewed for accuracy by our Medical Advisory Board.

Educational purpose only · Not a substitute for professional judgment or the full text of guidelines and labels.

Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 · View editorial policy

Cervical Cancer Screening With Pap Smears in Average‑Risk Females

For average‑risk individuals with a cervix, screening with cervical cytology (Pap test) is recommended every 3 years from age 21 through age 65. [1]

Screening is not recommended before age 21. [1]

Guideline‑Recommended Ages and Intervals (Pap Smear Alone)

Start age

  • Age 21 years is the recommended starting point for Pap test–based screening in average‑risk individuals. [1]

Screening interval

  • Every 3 years is recommended for Pap test (cytology) screening. [1]

Stopping age

  • Routine screening is not recommended after age 65 years when prior screening has been adequate and the individual is not otherwise at high risk. [1]
  • “Adequate prior screening” is defined by major guideline frameworks as 3 consecutive negative cytology results or 2 consecutive negative cotesting results within the relevant look‑back window. [1]

High‑Risk Populations Where Pap Interval Changes

The average‑risk Pap test schedule is not applicable to people at higher risk (examples include immunocompromised status such as HIV, in utero diethylstilbestrol exposure, and history of high‑grade cervical precancer or cancer). [1]

Immunocompromised Populations (Including HIV)

For individuals with HIV or other immunocompromising conditions, screening is recommended at more frequent intervals than the average‑risk 3‑year schedule. [2]

  • Cytology every year is recommended for adults with an immunocompromising medical condition in CDC STI guidance. [2]
  • After three consecutive annual normal cytology tests, screening may be spaced to every 3 years (CDC STI guidance). [2]
  • Screening is generally framed as not having a finite stop age in CDC STI guidance for immunocompromised individuals. [2]

Prior High‑Grade Precancer or Cervical Cancer

History of CIN 2 or CIN 3 (histologic HSIL) within the prior 25 years is managed with surveillance intervals that are different from average‑risk screening. [2]

  • Initial surveillance after CIN 2/3 includes HPV testing alone or with cytology at 6, 18, and 30 months, or cytology at 6, 12, 18, 24, and 30 months (CDC STI guidance). [2]
  • Long‑term surveillance is then performed every 3 years (CDC STI guidance), including continued follow‑up beyond age 65. [2]

Practical Differences in Interval Between Average‑Risk and High‑Risk

The average‑risk Pap schedule is 3‑year spacing. [1]

High‑risk guidance commonly starts with annual testing and then may extend to longer intervals after repeated normal results (immunocompromised conditions such as HIV). [2]

For prior high‑grade precancer, surveillance uses time‑staged follow‑up (initial frequent testing followed by prolonged long‑term surveillance), not the routine 3‑year screening interval. [2]

Related Questions